Literature DB >> 29151253

A Two-Week Fecal Microbiota Transplantation Course in Pediatric Patients with Inflammatory Bowel Disease.

Katarzyna Karolewska-Bochenek1, Pawel Grzesiowski2, Aleksandra Banaszkiewicz1, Agnieszka Gawronska1, Maria Kotowska1, Marcin Dziekiewicz1, Piotr Albrecht1, Andrzej Radzikowski1, Izabella Lazowska-Przeorek3.   

Abstract

Dysbiosis plays a major role in the etiology of inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) is a new promising option for IBD treatment. We aimed to assess the effectiveness of a two-week FMT course in children with IBD. Ten patients, 10-17 years of age with moderate to severe IBD received a course of eight doses of freshly prepared FMT via a naso-duodenal tube or gastroscopy. All of the patients had pancolitis. There were eight cases of ulcerative colitis (UC) and two of Crohn's disease (CD). Disease activity was evaluated using the Pediatric UC Activity Index (PUCAI) and Pediatric CD Activity Index (PCDAI) for UC and CD, respectively, CRP, and fecal calprotectin on the day before the first infusion and then on the day before the next course of FMT. Clinical response, defined as a decrease of 15 points in either index, was observed in 9/10 patients (seven UC and two CD). Clinical remission, defined as a PCDAI score ≤ 10 and PUCAI score < 10 measured at the same time point, was observed in 3/8 UC patients and 2/2 CD patients. Side effects observed were self-limiting and benign. We conclude that a short, intensive course of FMT has a beneficial effect on UC and CD colitis. FMT was well-tolerated and safe. Nonetheless, an optimal protocol of FMT administration is crucial for treatment efficacy.

Entities:  

Keywords:  Children; Crohn’s disease; Fecal microbiota transplantation; Inflammatory bowel disease; Ulcerative colitis

Mesh:

Year:  2018        PMID: 29151253     DOI: 10.1007/5584_2017_123

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

1.  The Safety of Fecal Microbiota Transplantation for Crohn's Disease: Findings from A Long-Term Study.

Authors:  Honggang Wang; Bota Cui; Qianqian Li; Xiao Ding; Pan Li; Ting Zhang; Xiaozhong Yang; Guozhong Ji; Faming Zhang
Journal:  Adv Ther       Date:  2018-10-16       Impact factor: 3.845

2.  Increasing incidence of inflammatory bowel disease in children and adolescents: significance of environmental factors.

Authors:  Sowon Park; Yunkoo Kang; Hong Koh; Seung Kim
Journal:  Clin Exp Pediatr       Date:  2019-12-06

Review 3.  Secondary causes of inflammatory bowel diseases.

Authors:  Yezaz A Ghouri; Veysel Tahan; Bo Shen
Journal:  World J Gastroenterol       Date:  2020-07-28       Impact factor: 5.742

4.  Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis.

Authors:  Luciane de Fátima Caldeira; Helena H Borba; Fernanda S Tonin; Astrid Wiens; Fernando Fernandez-Llimos; Roberto Pontarolo
Journal:  PLoS One       Date:  2020-09-18       Impact factor: 3.240

Review 5.  Future Directions in Reducing Gastrointestinal Disorders in Children With ASD Using Fecal Microbiota Transplantation.

Authors:  Paulina Żebrowska; Izabela Łaczmańska; Łukasz Łaczmański
Journal:  Front Cell Infect Microbiol       Date:  2021-02-26       Impact factor: 5.293

Review 6.  Current and future applications of fecal microbiota transplantation for children.

Authors:  Chien-Chang Chen; Cheng-Hsun Chiu
Journal:  Biomed J       Date:  2021-11-12       Impact factor: 7.892

7.  An updated systematic review and meta-analysis of fecal microbiota transplantation for the treatment of ulcerative colitis.

Authors:  Taobi Huang; Jinlan Xu; Maoying Wang; Ke Pu; Longquan Li; Huiyun Zhang; Yuan Liang; Weiming Sun; Yuping Wang
Journal:  Medicine (Baltimore)       Date:  2022-07-29       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.